Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “ER-Negative PR-Negative HER2-Negative Breast Neoplasms”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableLooking for participantsNCT06582615
What this trial is testing

Food for Thought - A Nutrition Intervention for Women Undergoing Active Treatment for Triple Negative Breast Cancer

Who this might be right for
Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Triple-Negative Breast Carcinoma
Ohio State University Comprehensive Cancer Center 60
Testing effectiveness (Phase 2)Looking for participantsNCT06817525
What this trial is testing

Nab-P+Cb+PD1 Inhibitors as Neoadjuvant Therapy for Early TNBC

Who this might be right for
Triple-negative Breast Cancer
Henan Cancer Hospital 64
Testing effectiveness (Phase 2)WithdrawnNCT06084689
What this trial is testing

Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures

Who this might be right for
Adult Soft Tissue SarcomaNon Small Cell Lung CancerTriple Negative Breast Cancer+2 more
Institut Bergonié
Large-scale testing (Phase 3)Looking for participantsNCT05862064
What this trial is testing

A Multi-center, Randomized, Open-label, Phase III Study Comparing PD-1 Inhibitor Combined With Antivascular Therapy and Anthracycline/Taxane-based Adjuvant Chemotherapy Versus Anthracycline/Taxane-based Adjuvant Chemotherapy Alone in Patients With Operable Triple-negative Breast Cancer

Who this might be right for
TNBC - Triple-Negative Breast Cancer
Fudan University 606
Not applicableUnknownNCT02670668
What this trial is testing

Mutation of BRCA1/2 and Other Potential Genes in Triple-negative Breast Cancer

Who this might be right for
Breast Cancer
Fudan University 100
Early research (Phase 1)Study completedNCT05390710
What this trial is testing

PhI to Solid Tumors and PhII to Locally Advanced or mTNBC

Who this might be right for
Solid TumorTNBC - Triple-Negative Breast Cancer
Laekna Limited 21
Testing effectiveness (Phase 2)WithdrawnNCT01100489
What this trial is testing

Breast-Conserving Surgery Followed by Radiation Therapy With MRI-Detected Stage I or Stage II Breast Cancer

Who this might be right for
Ductal Breast Carcinoma in SituEstrogen Receptor-negative Breast CancerEstrogen Receptor-positive Breast Cancer+13 more
Case Comprehensive Cancer Center
Testing effectiveness (Phase 2)Looking for participantsNCT06353997
What this trial is testing

Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients

Who this might be right for
Triple Negative Breast Cancer
Providence Health & Services 12
Testing effectiveness (Phase 2)UnknownNCT05103917
What this trial is testing

Assess the Safety, Tolerability and Antitumor Activity of X4P-001 in Combination With TNBC

Who this might be right for
Triple Negative Breast Cancer
Abbisko Therapeutics Co, Ltd 24
Testing effectiveness (Phase 2)Study completedNCT03301350
What this trial is testing

Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer

Who this might be right for
Breast CancerTriple Negative Breast Cancer
University of Wisconsin, Madison 29
Post-approval studies (Phase 4)Not Yet RecruitingNCT05843292
What this trial is testing

Short-term Sintilimab in Combination With Taxane and Carboplatin for Neoadjuvant Therapy in Triple-negative Breast Cancer

Who this might be right for
Triple-negative Breast Cancer
Shanghai Jiao Tong University School of Medicine 48
Testing effectiveness (Phase 2)WithdrawnNCT06938711
What this trial is testing

A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Context Therapeutics Inc.
Not applicableStudy completedNCT02158507
What this trial is testing

Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer

Who this might be right for
Metastatic Triple Negative Breast Cancer
University of Alabama at Birmingham 20
Testing effectiveness (Phase 2)Looking for participantsNCT05579366
What this trial is testing

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Who this might be right for
High Grade Epithelial Ovarian CancerHigh Grade Serous Ovarian CancerPrimary Peritoneal Carcinoma+12 more
Genmab 884
Testing effectiveness (Phase 2)Active Not RecruitingNCT04373031
What this trial is testing

Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast Cancer

Who this might be right for
Breast CancerBreast Neoplasms
Providence Health & Services 12
Early research (Phase 1)Study completedNCT03849469
What this trial is testing

XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors

Who this might be right for
MelanomaCervical CarcinomaPancreatic Carcinoma+20 more
Xencor, Inc. 78
Testing effectiveness (Phase 2)Looking for participantsNCT05660083
What this trial is testing

Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)

Who this might be right for
HER2-negative Breast CancerMetastatic Breast CancerMetaplastic Breast Carcinoma+1 more
The Methodist Hospital Research Institute 36
Testing effectiveness (Phase 2)Ended earlyNCT03992131
What this trial is testing

Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)

Who this might be right for
Ovarian CancerTriple-negative Breast CancerUrothelial Carcinoma+1 more
pharmaand GmbH 25
Early research (Phase 1)Ended earlyNCT04504331
What this trial is testing

Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer

Who this might be right for
Breast CancerHER2-negative Breast CancerER Positive Breast Cancer+1 more
Jennifer Lee Caswell-Jin 4
Early research (Phase 1)Looking for participantsNCT02926690
What this trial is testing

Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer

Who this might be right for
Relapsed/Refractory Locally Advanced or Metastatic Breast Cancer and Triple Negative Breast Cancer
OncoTherapy Science, Inc. 70
Next Page